GET DAILY SIGNALSNovaBridge Biosciences (NBP): $9 Target Points to +550% Upside from Current Levels
Key Takeaways
- The central $9.00 stock price target is the arithmetic mean of the two verified analyst price targets currently covering NBP, both of which sit at $9.00.
- With the stock near $1.37, the target implies upside of roughly 550% or more — an extremely large move that reflects both the depth of the decline and the early-stage nature of the business.
- The analyst range is unusually narrow ($9.00 low to $9.00 high) because only two analysts publish targets, and both rate the shares Buy or Strong Buy.
- The strongest support is clinical progress on the lead asset givastomig, including Fast Track designation and potential Accelerated Approval eligibility.
- The biggest risks are ongoing cash burn, likely future dilution, and binary clinical-trial outcomes typical of a small-cap biotechnology company.
- You can find more detail on the ticker's Major News, Today's Price Move, Forecast, and Earnings on additional pages.
- Explore Trending AI Robots to see AI-driven strategies monitoring stocks and ETFs across changing market conditions.
Analyst Price Targets and Consensus View
NovaBridge Biosciences is a clinical-stage biotechnology company that develops immuno-oncology treatments for cancer. Its American Depositary Shares (ADS) trade on Nasdaq under the ticker NBP after the company, formerly known as I-Mab, rebranded and changed its symbol in late 2025. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Only two analysts currently publish price targets for the stock, and both place their target at $9.00, producing a calculated mean of $9.00 with a range of $9.00 to $9.00. The most prominent is H.C. Wainwright's Andres Y. Maldonado, who resumed coverage with a Buy rating and a $9.00 target in February 2026 (raised from $7.00) and has reiterated that figure multiple times through 2026. A second analyst contributes a matching $9.00 target, which is why the overall mean, median, high, and low all converge at $9.00. Independent aggregators describe the view as a Strong Buy or Moderate Buy consensus.
The uniformity of the targets says less about certainty than about thin coverage: with only two contributors, the "analyst consensus" is narrow by construction. The $9.00 figure represents a research-horizon valuation of the lead program and pipeline rather than a near-term trading level.
Current Market Position and Path Toward the Target
The shares recently traded near $1.37, leaving the stock down more than 70% over the trailing year. Reaching $9.00 from that level would require a gain of roughly 550% or more — an extremely large move by any standard and one far outside the range of a typical 12-month price adjustment for a more established company.
A path toward the target would most plausibly run through clinical and regulatory milestones for givastomig, NovaBridge Biosciences' lead bispecific antibody being developed for gastroesophageal cancers. Positive data, a successful regulatory filing, or a partnership with a larger pharmaceutical company could each re-rate the shares significantly. The gap between the current price and the target reflects investor skepticism about whether these milestones will be achieved, not a modest valuation adjustment.
What Could Support a Move Toward the Target
- Givastomig has received Fast Track designation and feedback suggesting potential Accelerated Approval eligibility in first-line HER2-negative advanced gastroesophageal cancer, which analysts cite as evidence of a differentiated profile.
- H.C. Wainwright describes givastomig as a potential best-in-class bispecific antibody for frontline immune-chemotherapy combinations, a large commercial market.
- The pipeline offers additional optionality, including VIS-101 for neovascular age-related macular degeneration (nAMD) and a "hub-and-spoke" model for sourcing external assets.
- Analyst reiterations have been consistently positive, with the Buy rating and $9.00 target maintained across multiple updates in 2026.
What Could Prevent the Target From Being Reached
- As a clinical-stage company with no meaningful revenue, NovaBridge Biosciences continues to post losses, and consensus estimates point to negative EPS (earnings per share) through at least 2028.
- Financing clinical development typically requires additional capital, which can dilute existing shareholders and weigh on the share price.
- Clinical programs carry binary risk: a failed or disappointing trial readout could materially undermine the valuation that supports the $9.00 target.
- The stock's steep decline suggests broad investor skepticism about execution, and thin analyst coverage means the consensus view is fragile.
Technical Levels and Market Structure
Meaningful technical reference points are limited for a stock that has lost the large majority of its value over the past year. The dominant feature of the chart is a prolonged downtrend rather than a well-defined trading range, and durable support and resistance levels have not been firmly established at current prices. Round-number psychological levels such as $1.00 and $2.00 may act as informal markers, but for a micro-cap biotechnology name, fundamentals and clinical news are likely to matter far more than chart structure.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though the actual horizon can vary by firm and by the timing of expected catalysts. For NBP, investors should watch clinical data updates and regulatory communications on givastomig, any guidance or disclosures around Accelerated Approval or Fast Track pathways, financing or partnership announcements, and quarterly earnings reports that reveal the cash position and burn rate. Revisions to the two analysts' targets — in either direction — would also be an important signal.
Using Tickeron’s AI Daily Buy/Sell Signals for Ongoing Monitoring
In my view, systematic tools help keep track of fast-moving names like this one. Tickeron’s AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals as market conditions, technical behavior, and AI-driven analysis evolve. The tool is designed to help traders discover opportunities, track existing positions, and spot changing trends more efficiently than manual screening. For a volatile name like NovaBridge Biosciences, systematic, rules-based monitoring can complement fundamental research by flagging shifts in momentum and risk in near-real time. From what I see, it has become a useful part of my own process for staying on top of clinical-stage biotech names without having to check every development manually.
Final Assessment
The $9.00 central target is the arithmetic mean of the two verified analyst price targets, both of which sit at $9.00 — meaning the range is narrow by virtue of thin coverage rather than agreement among a broad group of firms. From a price near $1.37, reaching that level would require an exceptionally large move of roughly 550% or more. The bullish case rests on clinical and regulatory progress for givastomig and optionality in the broader pipeline, while the bearish case centers on continued losses, likely dilution, and the binary risk of clinical development. Because the gap between the current price and the target is so wide, investors should treat $9.00 as a research-driven valuation of success scenarios rather than a near-term forecast, and focus monitoring on clinical data, regulatory feedback, and the company's financing and cash position. No outcome is guaranteed, and the article is not a recommendation to buy or sell.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NBP sees its Stochastic Oscillator ascends from oversold territory
On October 20, 2026, the Stochastic Oscillator for NBP moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 68 instances where the indicator left the oversold zone. In 56 of the 68 cases the stock moved higher in the following days. This puts the odds of a move higher at over 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NBP's RSI Indicator exited the oversold zone, 26 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for NBP just turned positive on October 08, 2026. Looking at past instances where NBP's MACD turned positive, the stock continued to rise in 29 of 39 cases over the following month. The odds of a continued upward trend are 74%.
Following a +13.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where NBP advanced for three days, in 165 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
NBP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NBP as a result. In 82 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NBP entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.722) is normal, around the industry mean (3.037). P/E Ratio (-1.819) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. NBP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NBP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical stage biopharmaceutical company, which engages in developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.
Industry Biotechnology
Advertisement